During the SECRETED project, work is undertaken on the development of formulations that allow nucleic acids and siRNAs to be potentially released into ocular tissues. Particularly relevant is the exploration of new biodegradable surfactants that may have an iron chelating function relevant to ocular pathologies. Sylentis, in collaboration with Sphera Encapsulation, has been actively working on developing different prototypes of nanoparticles with novel surfactants obtained from the SECRETED consortium that could be further developed as new delivery tools.
These innovative carriers are being designed to enhance tissue penetration, addressing major challenges in the effective delivery of RNA-based therapies for ocular diseases.
By integrating advanced materials science with therapeutic innovation, the SECRETED project opens new avenues for drug delivery in ophthalmology.
